Data presented at American College of Cardiology 2018 Scientific Sessions (ACC; 10–12 March, Orlando, USA) indicate that a novel multi-protein, artificial intelligence (AI)-driven test accurately diagnoses aortic stenosis—a condition with a 50% mortality-rate when left untreated. The HART AS test was developed by medical technology company Prevencio.
HART AS identifies the presence of aortic stenosis and predicts the need for future medical intervention. Researchers believe the data can assist patients in getting guideline-recommended serial evaluations proven to enhance health outcomes. It could also lead to the use of this test as a more widely available, less expensive, and more accurate test than echocardiography.
“The HART AS blood test holds significant promise for earlier diagnosis and treatment of many more patients with aortic stenosis,” said James L Januzzi, practicing cardiologist at Massachusetts General Hospital and professor of Medicine at Harvard Medical School. Januzzi served as principal investigator on the team of researchers that conducted the study. They found that when patients were divided into low-risk and high-risk categories, the test predicted with 98% accuracy to exclude severe aortic stenosis.
“There are several inconsistencies with echocardiographic assessment that can hinder timely clinical decisions,” Januzzi added. “With the increasing use of minimally invasive aortic valve replacement, HART AS is well-positioned to assist in providing more appropriate care of patients.”
Employing a novel approach powered by AI, the company has produced five blood tests to-date that significantly improve diagnoses for a variety of heart and blood vessel-related complications.
The company’s range of tests currently include:
- HART CADTM: obstructive coronary artery disease diagnosis
- HART CVETM: 1-year risk of heart attack, stroke or cardiac death
- HART PADTM: peripheral artery disease diagnosis
- HART ASTM: aortic valve stenosis
- HART AMPTM: risk of amputation
HART test results have been presented at leading cardiovascular meetings (European Society of Cardiology Congress Scientific Sessions—2016, American College of Cardiology Scientific Sessions— 2017, American Heart Association Scientific Sessions—2017, American College of Cardiology Scientific Sessions—2018) and published in top-tier cardiology journals (Journal of American College of Cardiology—March 2017 and American Journal of Cardiology—July 2017).